{"analyses":[{"groupDescription":"The proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine and the combined non-vaccine arms at 6 months Post Transplant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9376","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine arm and lenalidomide/GM-CSF arm at 6 months Post Transplant.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4887","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine arm and lenalidomide alone arm at 6 months Post Transplant.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5176","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between lenalidomide/GM-CSF arm and lenalidomide alone arm at 6 months Post Transplant.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2461","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"The proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine and the combined non-vaccine arms at 1 year Post Transplant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2530","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine arm and lenalidomide/GM-CSF arm at 1 year Post Transplant.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2213","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine arm and lenalidomide alone arm at 1 year Post Transplant.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4930","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the lenalidomide/GM-CSF arm and lenalidomide alone arm at 1 year Post Transplant.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6591","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"The proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine and the combined non-vaccine arms at 2 years Post Transplant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6790","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine arm and lenalidomide/GM-CSF arm at 2 years Post Transplant.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3124","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the vaccine arm and lenalidomide alone arm at 2 years Post Transplant.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7379","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"In this pairwise analysis, the proportion of participants alive and with sCR/CR/VGPR will be compared between the lenalidomide/GM-CSF arm and lenalidomide alone arm at 2 years Post Transplant.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2379","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05.","statisticalMethod":"Chi-squared"},{"groupDescription":"Proportion of participants achieving CR among the subset of participants who are not in CR at the time of randomization between the vaccine and the combined non-vaccine arms at 6 months Post Transplant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5353","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"Proportion of participants achieving CR among the subset of participants who are not in CR at the time of randomization between the vaccine and the combined non-vaccine arms at 12 months Post Transplant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4417","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"Proportion of participants achieving CR among the subset of participants who are not in CR at the time of randomization between the vaccine and the combined non-vaccine arms at 24 months Post Transplant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9450","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"A pairwise analysis of proportion of participants achieving CR among the subset of participants who are not in CR at the time of randomization between the vaccine arm and lenalidomide/GM-CSF arm is conducted at 1 year post transplant.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1599","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"A pairwise analysis of proportion of participants achieving CR among the subset of participants who are not in CR at the time of randomization between the vaccine arm and lenalidomide alone arm is conducted at 1 year post transplant.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8984","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"},{"groupDescription":"A pairwise analysis of proportion of participants achieving CR among the subset of participants who are not in CR at the time of randomization between lenalidomide/GM-CSF arm and lenalidomide alone arm is conducted at 1 year post transplant.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1757","pValueComment":"Statistical significance was determined using a pre-specified threshold of 0.05","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"8"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"title":"Not Evaluable"}],"title":"Disease Status at 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"title":"Not Evaluable"}],"title":"Disease Status at 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"3"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"}],"title":"Not Evaluable"}],"title":"Disease Status at 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"14"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"11"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 3 (Day 57 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"10"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 6 (Day 141 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"15"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 9 (Day 225 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 12 (Day 309 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"13"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"6"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 15 (Day 393 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"6"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 18 (Day 477 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"6"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 21 (Day 561 Assessment)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}],"title":"Stringent Complete Response (sCR)"},{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"6"}],"title":"Very Good Partial Remission (VGPR)"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"title":"Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"title":"Dead"},{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"}],"title":"Not Evaluable"}],"title":"Disease Status at Cycle 24 (Day 654 Assessment)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"35"}],"units":"Participants"}],"description":"A participant's disease status is evaluated based on the International Uniform Response Criteria per protocol. Before disease progression (PD), all disease classifications including stringent complete response (sCR), complete response (CR), very good partial remission (VGPR), partial response (PR), stable disease (SD) are relative to participant's disease status at study entry. Disease status is 'Not Evaluable' when disease assessment is not required, or disease status is missing.","groups":[{"description":"Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.\n\nTumor Cell Collection: Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell will be isolated and frozen for subsequent vaccine generation.\n\nAutologous Stem Cell Transplant: Patients will receive an autologous graft of a minimum cell dose of 2.0 x 10\\^6 CD34+ cells/kg patient actual body weight per transplantation with high-dose melphalan of 200mg/m\\^2 at the schedule and timing according to institutional practices.\n\nLeukapheresis: Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.\n\nLenalidomide: Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.\n\nMyeloma vaccine: The target dose is 3 x 10\\^6 fusion cells per vaccine. A minimum of 3 x 10\\^6 total fusion cells will be required to proceed with vaccine administration. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance.\n\nGM-CSF: 100 ug GM-CSF will be given for a total of 4 days of each cycle.","id":"OG000","title":"Lenalidomide, Vaccine, and GM-CSF"},{"description":"Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.\n\nTumor Cell Collection: Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).\n\nAutologous Stem Cell Transplant: Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.\n\nMelphalan: Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\\^2 at the schedule and timing according to institutional practices.\n\nLenalidomide: Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.\n\nGM-CSF: 100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.","id":"OG001","title":"Lenalidomide and GM-CSF"},{"description":"Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.\n\nTumor Cell Collection: Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).\n\nAutologous Stem Cell Transplant: Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.\n\nMelphalan: Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\\^2 at the schedule and timing according to institutional practices.\n\nLenalidomide: Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.","id":"OG002","title":"Maintenance Lenalidomide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis Population includes transplanted participants.","reportingStatus":"POSTED","timeFrame":"6 months, 1 year, and 2 years post-transplant and at Cycles 3(Day 57), 6(Day 141), 9(Day 225), 12(Day 309), 15 (Day 393), 18(Day 477), 21(Day 561) and 24(Day 654) of maintenance therapy","title":"Participants Response to Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}